2nd Edition of International Cancer & Immuno-Oncology Conference
March 19-21, 2026 | Singapore
Cholangiocarcinoma
Cholangiocarcinoma, a rare and aggressive form of cancer, originates in the bile ducts of the liver. Despite its rarity, its incidence is steadily rising globally, presenting significant challenges in diagnosis and treatment. Researchers are delving into various aspects of cholangiocarcinoma, from its molecular mechanisms to novel therapeutic approaches. Understanding its genetic drivers, such as mutations in the IDH1 and IDH2 genes, offers potential targets for precision medicine. Additionally, advancements in imaging technologies aid in early detection, crucial for improving prognosis. Immunotherapy and targeted therapies show promise in clinical trials, offering new avenues for personalized treatment strategies. Collaborative efforts between clinicians, scientists, and pharmaceutical companies are essential in advancing our knowledge and developing effective therapies to combat this formidable disease.
Rajvir Dahiya
University of California San Francisco, United States
Atif A Ahmed
University of Washington-Seattle Children’s Hospital, United States
Anyou Wang
DIFIBER LLC, United States
Paulo Cesar De Morais
Catholic University of Brasilia, Brazil
Allen Chen
Olympic Medical Center, United States
Shilpa S Dhar
UT MD Anderson Cancer Center, United States
Ritu Khanna
University of Manchester, United KingdomSubmit your abstract Today
Title : A novel blood-based mRNA genomics technology for cancer diagnosis and treatment
Rajvir Dahiya, University of California San Francisco, United States
Title : tRNA-derived fragment 3′tRF-AlaAGC modulates cell chemoresistance and M2 macrophage polarization via binding to TRADD in breast cancer
Feng Yan, The Affiliated Cancer Hospital of Nanjing Medical University, China
Title : Integrating single-cell and spatial transcriptomics to uncover and elucidate GP73-mediated pro-angiogenic regulatory networks in hepatocellular carcinoma
Jiazhou Ye, Guangxi Medical University Cancer Hospital, China
Title : Unveiling the synergism of radiofrequency therapy and graphene nanocomposite in tumor cell viability assay
Paulo Cesar De Morais, Catholic University of Brasilia, Brazil
Title : Analysis of the dynamic evolution and influencing factors of nutritional risk in breast cancer patients during treatment
Jingwen Yan, Sun Yat-sen University, China
Title : Integrative multi-omics reveals metabolic–stemness coupling and novel therapeutic targets in osteosarcoma chemoresistance
Jinyan Feng, Tianjin Medical University Cancer Institute and Hospital, China